Literature DB >> 23168558

Endobronchial instillations of amphotericin B: complementary treatment for pulmonary mucormycosis.

Inmaculada Alfageme1, Angela Reina, Javier Gallego, Nuria Reyes, Angeles Torres.   

Abstract

Pulmonary mucormycosis is a rare fungal infection that appears in patients with hematologic diseases who are immunosuppressed by chemotherapy. We report a case of pulmonary mucormycosis in a 21-year-old man with acute lymphoblastic leukaemia. During the period of pancytopenia he developed invasive mucormycosis. His initial symptoms were pleuritic chest pain with fever and unresponsiveness to broad-spectrum antibiotics. The outcome was favorable after long-term systemic and aerosolized amphotericin B, endobronchial instillations of amphotericin B, posaconazole, and surgery.

Entities:  

Year:  2009        PMID: 23168558     DOI: 10.1097/LBR.0b013e3181aa2583

Source DB:  PubMed          Journal:  J Bronchology Interv Pulmonol        ISSN: 1948-8270


  4 in total

Review 1.  Pulmonary Mucormycosis Over 130 Years: A Case Report and Literature Review.

Authors:  Hasan S Yamin; Amro Y Alastal; Izzedin Bakri
Journal:  Turk Thorac J       Date:  2017-01-01

2.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

3.  Bronchoscopic instillation of liposomal amphotericin B in management of nonresponding endobronchial mucormycosis.

Authors:  Loganathan Nattusamy; Umasankar Kalai; Vijay Hadda; Anant Mohan; Randeep Guleria; Karan Madan
Journal:  Lung India       Date:  2017 Mar-Apr

Review 4.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.